Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199962 | 0.98 | CES1 (0.50) | CES1HTTMAPK1HPGDERCC5 | |
| SCHEMBL29645048 | 0.98 | CES1 (0.50) | CES1HTTMAPK1HPGDERCC5 | |
| SCHEMBL29137330 | 0.83 | HPGD (0.44) | HTTHPGDERCC5FEN1ALDH1A1 | |
| SCHEMBL1278673 | 0.82 | HPGD (0.43) | HTTHPGDERCC5FEN1ALDH1A1 | |
| SCHEMBL1278501 | 0.82 | HPGD (0.43) | HTTHPGDERCC5FEN1ALDH1A1 | |
| SCHEMBL28181777 | 0.82 | TRPA1 (0.45) | CES1HTTMAPK1HPGDALDH1A1 | |
| SCHEMBL8957439 | 0.80 | ALDH1A1 (0.60) | CES1HTTHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL7949878 | 0.78 | HPGD (0.47) | HTTHPGDERCC5FEN1ALDH1A1 | |
| Toluic Acid SCHEMBL4746481 | 0.78 | ALDH1A1 (0.52) | HTTHPGDERCC5FEN1ALDH1A1 | |
| SCHEMBL8955453 | 0.77 | PTPN1 (0.48) | HPGDERCC5FEN1ALDH1A1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441946-B2 | Linear alpha-olefin catalysts and preparation and use thereof | APALENE TECHNOLOGY CO., LTD. (HANGZHOU) (CN) | 2019-10-15 | — | — | US | disclosed |
| US-20180147571-A1 | NOVEL LINEAR ALPHA-OLEFIN CATALYSTS AND PREPARATION AND USE THEREOF | APALENE TECHNOLOGY CO., LTD. (JIAXING) (CN) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147571-A1 | NOVEL LINEAR ALPHA-OLEFIN CATALYSTS AND PREPARATION AND USE THEREOF | UBE2L3, RNF168, AGL | CES1 3464/4885HTT 4204/4885MAPK1 3255/4885 |
| US-10441946-B2 | Linear alpha-olefin catalysts and preparation and use thereof | UBE2L3, COG8, ACSL3 | CES1 3277/4885HTT 4129/4885MAPK1 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.